Baker Bros. Advisors’s Passage Bio PASG Stock Holding History

Baker Bros. Advisors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,858	Closed	-$276K	–	123
2022 Q2	$276K	Hold	5,858	–	–	﹤0.01%	114
2022 Q1	$363K	Hold	5,858	–	–	﹤0.01%	116
2021 Q4	$744K	Hold	5,858	–	–	﹤0.01%	119
2021 Q3	$1.17M	Hold	5,858	–	–	0.01%	117
2021 Q2	$1.55M	Sell	5,858 -5,910	-50%	-$1.83M	0.01%	113
2021 Q1	$4.11M	Hold	11,768	–	–	0.02%	100
2020 Q4	$6.02M	Sell	11,768 -1,285	-10%	-$515K	0.02%	89
2020 Q3	$3.42M	Sell	13,053 -697	-5%	-$240K	0.01%	88
2020 Q2	$7.52M	Hold	13,750	–	–	0.03%	71
2020 Q1	$4.33M	Buy	+13,750	New	+$4.3M	0.03%	68

Other funds holding PASG

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Baker Bros. Advisors's PASG Position: Q3 2022 in Review

Baker Bros. Advisors sold out of Passage Bio (PASG) in Q3 2022, closing a stake of 5,858 shares — an estimated $276K sold.

Baker Bros. Advisors first reported a position in PASG in Q1 2020 and held it in 10 quarters. The position peaked at $7.52M in Q2 2020. 75 funds tracked by Wall St. Rank hold PASG as of Q3 2022.

Baker Bros. Advisors reported no remaining Passage Bio position as of Q3 2022 after selling out during the quarter.
Baker Bros. Advisors sold 5,858 Passage Bio shares in Q3 2022, an estimated $276K.
Baker Bros. Advisors first reported a position in Passage Bio in Q1 2020 and held it in 10 quarters.
Baker Bros. Advisors's Passage Bio position peaked at $7.52M in Q2 2020.
75 funds tracked by Wall St. Rank held Passage Bio as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.